Home Tags Cancer: Breast

Tag: Cancer: Breast

For patients with metastatic breast cancer

Patient Cost Responsibility Up for Guideline-Discordant Care

Guideline-discordant tx linked to $1,841 higher patient costs in first year in metastatic breast cancer
Unselected

Multigene Testing for All Breast Cancer Patients Cost-Effective

Findings support expansion of genetic testing to all women with breast cancer
Treatment of male breast cancer has evolved since 2004

Treatment of Male Breast Cancer Has Evolved From 2004 to 2014

Significant increases seen in total mastectomy, radiotherapy after breast conservation, endocrine tx
The addition of abemaciclib to fulvestrant provides a statistically significant and clinically meaningful gain in median overall survival

Drug Combo Extends Survival in Advanced Breast Cancer

Benefit seen for addition of CDK4/6 inhibitor after progression of disease on endocrine therapy
The breast cancer death rate is continuing to decline

Breast Cancer Mortality Rate Continues to Decline in the U.S.

Pace of decline slowed from 1.9 percent during 1998 to 2011 to 1.3 percent during 2011 to 2017
Male breast cancer patients have higher mortality after cancer diagnosis than female patients

Higher Mortality Seen for Male Breast Cancer Patients

Clinical characteristics, undertreatment correlated with 63.3 percent excess mortality rate for men
Screening for breast cancer in men has increased over time

Screening for Breast Cancer in Men Has Increased Over Time

Risk higher for older age, Ashkenazi descent, genetic mutations, and personal, first-degree family hx
Maintaining full doses of chemotherapy

Full Chemo Doses May Improve Survival in Breast Cancer

Maintaining full doses of chemo especially important early in the treatment course
For older women

Mammos May Not Benefit Elderly Women With Chronic Illness

Risk for death from other causes much higher than risk for breast cancer death with increasing comorbidity, age
The U.S. Preventive Services Task Force recommends that clinicians offer risk-reducing medications to women at increased breast cancer risk. These recommendations form the basis of a final recommendation statement published in the Sept. 3 issue of the Journal of the American Medical Association.

USPSTF Advises Meds to Reduce Risk for Primary Breast Cancer

Offer risk-reducing meds to women at higher risk for breast cancer, low risk for adverse medication effects